https://www.bioworld.com/rss en-us http://www.bioworld.com/articles/726152 Tue, 11 Nov 2025 10:00:00 -0500 https://www.bioworld.com/articles/726152-advancell-sets-new-radiopharma-standard-in-prostate-cancer 3D illustration showing presence of tumor inside prostate gland http://www.bioworld.com/articles/726135 Fri, 07 Nov 2025 10:00:00 -0500 https://www.bioworld.com/articles/726135-advancell-sets-new-radiopharma-standard-in-prostate-cancer 3D illustration showing presence of tumor inside prostate gland http://www.bioworld.com/articles/725876 Thu, 06 Nov 2025 10:00:00 -0500 https://www.bioworld.com/articles/725876-advancell-sets-new-radiopharma-standard-in-prostate-cancer 3D illustration showing presence of tumor inside prostate gland http://www.bioworld.com/articles/719847 Wed, 07 May 2025 11:00:00 -0400 https://www.bioworld.com/articles/719847-therivas-vcn-01-improves-survival-in-phase-iib-pancreatic-cancer-trial Illustration of cancer in the pancreas http://www.bioworld.com/articles/716961 Tue, 04 Feb 2025 12:00:00 -0500 https://www.bioworld.com/articles/716961-radiopharma-advancell-raises-112m-in-series-c-for-alpha-therapies Vial of Advancell's Alpha-212 isotope Alpha 212 is the isotope Lead-212 and powers Advancell's therapeutic pipeline. Credit: Advancell Co. Ltd. http://www.bioworld.com/articles/715255 Wed, 11 Dec 2024 12:00:00 -0500 https://www.bioworld.com/articles/715255-wick-ed-good-phase-iii-prostate-cancer-data-light-up-candel Line graph arrow trending upward http://www.bioworld.com/articles/714615 Tue, 19 Nov 2024 12:00:00 -0500 https://www.bioworld.com/articles/714615-chinas-nmpa-accepts-ascentage-nda-for-bcl-2-inhibitor-lisaftoclax http://www.bioworld.com/articles/713531 Tue, 15 Oct 2024 12:00:00 -0400 https://www.bioworld.com/articles/713531-oncolytic-virus-therapy-may-soon-change-glioma-care-bio-japan Conceptual image for brain cancer treatment http://www.bioworld.com/articles/713425 Thu, 10 Oct 2024 12:00:00 -0400 https://www.bioworld.com/articles/713425-oncolytic-virus-therapy-may-soon-change-glioma-care-bio-japan Conceptual image for brain cancer treatment http://www.bioworld.com/articles/712833 Tue, 24 Sep 2024 12:00:00 -0400 https://www.bioworld.com/articles/712833-telix-expands-us-radiopharma-footprint-with-250m-rls-buy Acquisition puzzle http://www.bioworld.com/articles/711569 Wed, 14 Aug 2024 12:00:00 -0400 https://www.bioworld.com/articles/711569-verrica-produces-positive-basal-cell-data-then-stock-plunges http://www.bioworld.com/articles/710235 Tue, 02 Jul 2024 12:00:00 -0400 https://www.bioworld.com/articles/710235-radiopharm-raises-au70m-as-it-brings-on-new-investor-lantheus Australian money http://www.bioworld.com/articles/710004 Wed, 26 Jun 2024 12:00:00 -0400 https://www.bioworld.com/articles/710004-radiopharm-raises-au70m-as-it-brings-on-new-investor-lantheus Australian money http://www.bioworld.com/articles/707746 Wed, 17 Apr 2024 12:00:00 -0400 https://www.bioworld.com/articles/707746-theolytics-hauls-in-237m-for-oncolytic-virus-drug-theo-260 British pound symbol http://www.bioworld.com/articles/707172 Fri, 12 Apr 2024 12:00:00 -0400 https://www.bioworld.com/articles/707172-use-of-mixed-reality-visualization-to-improve-radiotherapy patient-alignment-12april24.jpg WO2024064111-A1, “Systems and methods of aligning a patient with a medical device leveraging outside-in tracking.”Assignee: University of FloridaInventors: Johnson, Perry, B.IPC Codes: G06T 15/00; G06T 7/73; G06T 7/30; A61B 90/00; A61B 34/10Publication Date: March 28, 2024Earliest priority details: US2022408711, Sept. 21, 2022 http://www.bioworld.com/articles/707384 Tue, 09 Apr 2024 12:00:00 -0400 https://www.bioworld.com/articles/707384-sino-biopharm-boehringer-partner-on-oncology-assets-in-china Sino-BI agreement signing Mohammed Tawil, Boehringer Ingelheim president and CEO for greater China (left), and Chengrun Xie, Sino Biopharma CEO, sign an agreement to develop Boehringer assets in China. http://www.bioworld.com/articles/707370 Mon, 08 Apr 2024 12:00:00 -0400 https://www.bioworld.com/articles/707370-sino-biopharm-boehringer-partner-on-oncology-assets-in-china Sino-BI agreement signing Mohammed Tawil, Boehringer Ingelheim president and CEO for greater China (left), and Chengrun Xie, Sino Biopharma CEO, sign an agreement to develop Boehringer assets in China. http://www.bioworld.com/articles/694091 Thu, 09 Feb 2023 09:00:00 -0500 https://www.bioworld.com/articles/694091-virogin-reports-on-in-vitro-and-in-vivo-research-with-vg-301-oncolytic-virus http://www.bioworld.com/articles/693083 Mon, 09 Jan 2023 09:00:00 -0500 https://www.bioworld.com/articles/693083-transgenes-intravenous-il-12-armed-oncolytic-virus-tg-6050-cleared-to-enter-clinic-trials-in-france http://www.bioworld.com/articles/692661 Wed, 21 Dec 2022 09:00:00 -0500 https://www.bioworld.com/articles/692661-orgenesis-reports-positive-preclinical-results-on-intranasal-administration-of-cell-based-oncolytic-virus-bearing-product-in-glioblastoma-model Oncolytic virus concept illustration http://www.bioworld.com/articles/337952 Wed, 24 Jul 2019 00:00:00 -0400 https://www.bioworld.com/articles/337952-startup-theolytics-exits-stealth-mode-with-veteran-team-and-goal-of-best-oncolytic-virus http://www.bioworld.com/articles/331711 Wed, 17 Jul 2019 00:00:00 -0400 https://www.bioworld.com/articles/331711-aussie-immuno-oncology-firm-imugene-bolsters-pipeline-with-oncolytic-virus-acquisition